Automated Manufacturing– tag –
-
Leman Biotech Raises RMB 200M (USD 29M) Series A+ to Advance Ultra-Low-Dose Metabolically Armored CAR-T to Phase I Trials and Automated Manufacturing Scale-Up
Insight, China's Pharmaceutical Industry China Overview Leman Biotech has secured RMB 200 million (approximately USD 29 million) in Series A+ funding to advance Phase I trials of its ultra-low-dose metabolically armored CAR-T cell therap... -
Technology Networks Delineates Commercialization Strategies for iPSC Therapies: Automated Manufacturing and Immune-Evasive Cell Line Development are Key
Technology Networks UK Overview Technology Networks provides an in-depth analysis of strategic challenges and solutions for the commercial viability of iPSC-based therapies, emphasizing the critical importance of scalable manufacturing, ... -
Cellura Report: Human Pluripotent Stem Cell Culture Evolves, Building Next-Gen Manufacturing with Chemically Defined Xeno-Free Media, Advanced Biomaterials, Automated Production, and Intelligent Control
Cellura Unknown Overview Cellura reports a significant evolution in human pluripotent stem cell (hPSC) culture towards more reliable and reproducible cell manufacturing. This transformation is characterized by a shift to chemically defin... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
Sonoma Biotherapeutics Automates Autologous CAR-Treg Therapy Manufacturing for Rheumatoid Arthritis with Cellares’ Cell Shuttle Platform
Regen Report USA Overview Sonoma Biotherapeutics partnered with Cellares to automate manufacturing of its Phase 1 autologous CAR-Treg therapy (SBT-77-7101) for treatment-resistant rheumatoid arthritis, using Cellares' Cell Shuttle platfo... -
Closed-System Semi-Automated Manufacturing Key to Expanding CAR-T Access in Low- and Middle-Income Countries by Reducing Cost and Complexity
PubMed International Overview CAR-T cell therapy adoption in low- and middle-income countries (LMICs) has been severely constrained by high costs, insufficient infrastructure, and complex regulatory demands. However, the advent of closed... -
CCRM, OmniaBio, and Avectas Partner to Enhance Cell Therapy Manufacturing with Automated Platform Evaluation
BioSpace Canada Overview CCRM and its CDMO subsidiary, OmniaBio Inc., have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This collaboration aims to explore how Avec... -
New Market Pitch Evaluates Top Cell Therapy Startups Including Orca Bio, Cellares, and Kelonia: Differentiated by Clinical, Manufacturing, and Strategic Advancements
New Market Pitch USA Overview New Market Pitch selected ten leading cell therapy startups—Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio—evaluating their regulatory maturity, clinical... -
Cellares and TScan Therapeutics Partner to Automate Manufacturing of TCR-T Therapy Candidate TSC-101 for Hematologic Malignancies, Accelerating Commercialization
OTC Markets (BusinessWire) USA Overview Cellares and TScan Therapeutics announced an agreement to evaluate the automated manufacturing of TSC-101, a TCR-T cell therapy candidate for patients with hematologic malignancies. This collaborat... -
Terumo BCT and Steminent Partner to Automate Mesenchymal Stem Cell Manufacturing for Late-Stage Clinical Commercialization
Terumo Blood and Cell Technologies Taiwan Overview Terumo Blood and Cell Technologies (Terumo BCT) and Taipei-based Steminent Biotherapeutics Inc. have announced a strategic collaboration to accelerate late-stage manufacturing readiness ...
1